159 related articles for article (PubMed ID: 36606299)
1. Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates.
Kim N; Kim YB
Radiat Oncol J; 2022 Dec; 40(4):216-224. PubMed ID: 36606299
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities.
Fiorentino A; Gregucci F; Mazzola R; Figlia V; Ricchetti F; Sicignano G; Giajlevra N; Ruggieri R; Fersino S; Naccarato S; Massocco A; Corradini S; Alongi F
Radiol Med; 2019 Apr; 124(4):309-314. PubMed ID: 30547358
[TBL] [Abstract][Full Text] [Related]
4. Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies.
Chatterjee S; Chakrabarty S; Santosham R; Saha A; Mallick I; Arunsingh M; Bhattacharya T; Achari R; Agrawal S; Ahmed R; Das J; Mahata A; Mandal S; Ray S
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1033-1042. PubMed ID: 36868522
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma.
Kim N; Lim DH; Choi JW; Lee JI; Kong DS; Seol HJ; Nam DH
Yonsei Med J; 2023 Feb; 64(2):94-103. PubMed ID: 36719016
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial.
Chatterjee S; Chakraborty S;
Trials; 2020 Sep; 21(1):819. PubMed ID: 32998747
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer.
Faria S; Ruo R; Perna M; Cury F; Duclos M; Sarshoghi A; Souhami L
Pract Radiat Oncol; 2020; 10(6):e514-e520. PubMed ID: 32738465
[TBL] [Abstract][Full Text] [Related]
8. Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.
Jain N; Sharma R; Sachdeva K; Kaur A; Sudan M
J Med Phys; 2022; 47(2):141-144. PubMed ID: 36212213
[TBL] [Abstract][Full Text] [Related]
9. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
10. Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer.
Nithiyananthan K; Creighton N; Currow D; Martin JM
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):417-423. PubMed ID: 33974884
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes after Dose-Escalated Moderately Hypofractionated Radiotherapy for Frail Patients with High-Grade Glioma.
Kim N; Shin H; Lim DH; Nam DH; Lee JI; Seol HJ; Kong DS; Choi JW; Chong K; Lee WJ
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201492
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.
Harris JP; Chang-Halpenny CN; Maxim PG; Quon A; Graves EE; Diehn M; Loo BW
Clin Lung Cancer; 2015 Nov; 16(6):475-85. PubMed ID: 25770888
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer.
Rico M; Martínez M; Rodríguez M; Rosas L; Barco A; Martínez E
J Clin Transl Res; 2021 Apr; 7(2):199-208. PubMed ID: 34104822
[TBL] [Abstract][Full Text] [Related]
14. HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis.
Chakraborty S; Chatterjee S;
Radiother Oncol; 2022 Sep; 174():59-68. PubMed ID: 35817323
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated and hyper-hypofractionated radiation therapy in postoperative breast cancer treatment.
Fang M; Marta GN
Rev Assoc Med Bras (1992); 2020 Sep; 66(9):1301-1306. PubMed ID: 33027462
[TBL] [Abstract][Full Text] [Related]
16. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionation for prostate cancer: an update.
Tiberi D; Vavassis P; Nguyen D; Yassa M
Expert Rev Endocrinol Metab; 2017 May; 12(3):199-205. PubMed ID: 30063454
[TBL] [Abstract][Full Text] [Related]
19. Comparative radiobiological analysis and preliminary results of Ultra hypofractionated accelerated radiotherapy for low-risk prostate cancer patients.
Nanos C; Souftas V; Zisimopoulos A; Abatzoglou I; Koukourakis MI
J BUON; 2021; 26(3):956-963. PubMed ID: 34268959
[TBL] [Abstract][Full Text] [Related]
20. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
Appelt AL; Vogelius IR; Bentzen SM
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):147-52. PubMed ID: 22910644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
